Alto Neuroscience (NYSE:ANRO) Upgraded by Wall Street Zen to “Sell” Rating

Wall Street Zen upgraded shares of Alto Neuroscience (NYSE:ANRO) from a strong sell rating to a sell rating in a research note published on Saturday morning.

Several other research firms have also issued reports on ANRO. Robert W. Baird cut their price target on shares of Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Zacks Research downgraded Alto Neuroscience from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 22nd. Chardan Capital reissued a “buy” rating and issued a $30.00 target price on shares of Alto Neuroscience in a research note on Wednesday, April 22nd. Bank of America began coverage on Alto Neuroscience in a report on Tuesday, May 5th. They set a “buy” rating and a $35.00 target price for the company. Finally, BTIG Research raised their price target on Alto Neuroscience from $28.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $36.62.

Alto Neuroscience Stock Performance

Shares of NYSE ANRO opened at $32.14 on Friday. The stock has a market cap of $1.13 billion, a price-to-earnings ratio of -13.28 and a beta of 1.06. The company has a current ratio of 14.85, a quick ratio of 20.52 and a debt-to-equity ratio of 0.07. Alto Neuroscience has a 1-year low of $3.05 and a 1-year high of $33.67. The stock’s 50-day moving average is $25.97 and its 200 day moving average is $22.75.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.08. On average, sell-side analysts anticipate that Alto Neuroscience will post -3 EPS for the current fiscal year.

Institutional Trading of Alto Neuroscience

Hedge funds have recently made changes to their positions in the stock. AWM Investment Company Inc. purchased a new stake in shares of Alto Neuroscience in the 2nd quarter worth approximately $2,111,000. Bank of New York Mellon Corp purchased a new position in Alto Neuroscience during the second quarter valued at $2,014,000. GK Wealth Management LLC purchased a new position in Alto Neuroscience during the second quarter valued at $226,000. Perceptive Advisors LLC boosted its holdings in Alto Neuroscience by 12.6% in the first quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock worth $45,182,000 after acquiring an additional 225,500 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in Alto Neuroscience by 131.5% in the first quarter. Bank of America Corp DE now owns 25,677 shares of the company’s stock worth $577,000 after acquiring an additional 14,585 shares in the last quarter.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.